


CLAIMS:

1. A compound of formula (I),



(I)

5

or a pharmaceutically acceptable derivative thereof, wherein:

X represents NR or O;

R represents hydrogen, C₁₋₈ alkyl or SO₂[C₁₋₈ alkyl];

W represents N or CH;

- 10 Y and Y' independently represent hydrogen, halogen, OH, CF₃, OCF₃, CN, NH₂, C₁₋₈ alkyl, C₁₋₈ alkyloxy or C₃₋₈ cycloalkyl;

Ring A represents a heterocyclic ring containing at least one nitrogen atom;

Z represents a direct link, C₁₋₈ alkyl or C₃₋₈ cycloalkyl;

R¹ represents R², OR², OR³-R⁴, N(R²)[C₁₋₈ alkylene]_aR⁴; NCOR², or SR⁴;

- 15 R² and R⁴ independently represent hydrogen, C₃₋₈ cycloalkyl, CF₃, Ar or Het;
R³ represents a direct link or C₁₋₈ alkyl;
a is 0 or 1;

Ar represents an aromatic ring, optionally fused to a heterocyclic ring, and/or optionally substituted with one or more groups as described below;

- 20 Het represents a heterocyclic ring optionally substituted with one or more groups as described below, and/or optionally fused to an aromatic ring which is optionally substituted with one or more groups as described below;

at each occurrence C₁₋₈alkyl, C₁₋₈alkylene and C₃₋₈cycloalkyl may be independently optionally substituted with one or more groups as described below;

- 25 substituent groups for Ar, Het, C₁₋₈alkyl, C₁₋₈alkylene and C₃₋₈cycloalkyl referred to above are independently selected from hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkyloxy, S[C₁₋₈alkyl], CN, CF₃, NH₂ and OH.

2. A compound according to claim 1, wherein X represents NR and R represents Me.

30

3. A compound according to claim 1 or claim 2, wherein W represents N.

4. A compound according to any of claims 1 to 3, wherein Ring A represents piperidinyl.
5. A compound according to any of claims 1 to 4, wherein Z is a direct link.
- 5 6. A compound according to claim 1, selected from
 - [4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-(1H-indol-3-yl)-methanone;
 - 1-[4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e] azulen-1-yl)-piperidin-1-yl]-2-o-tolyl-ethanone;
 - 10 [4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-(1-methyl-cyclohexyl)-methanone;
 - 1-[4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e] azulen-1-yl)-piperidin-1-yl]-2-cyclopropyl-ethanone;
 - 15 [4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-(1H-indol-2-yl)-methanone;
 - [4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-(2-hydroxy-5-methyl-phenyl)-methanone;
 - [4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-(1H-indol-6-yl)-methanone;
 - 20 [4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-(3-methoxy-phenyl)-methanone ;
 - [4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-(3-fluoro-phenyl)-methanone;
 - 25 [4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-(4-fluoro-phenyl)-methanone;
 - 1-[4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-butan-1-one;
 - [4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-cyclopropyl-methanone; and
 - 30 pharmaceutically acceptable derivatives thereof.
7. The use of a compound according to any of claims 1 to 6 as a medicament.
- 35 8. A method of treatment of anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea

(primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittelschmerz, preclampsia, premature ejaculation, premature (preterm) labor or Raynaud's disease, comprising administering a therapeutically effective amount of a compound according to any
5 of claims 1 to 6 to a patient suffering from such a disorder.

9. A method according to claim 7 wherein the disorder is dysmenorrhoea (primary or secondary).

10 10. A method according to claim 9 wherein the disorder is primary dysmenorrhoea.

11. The use of a compound according to any of claims 1 to 6 in the manufacture of a medicament for the treatment of anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea
15 (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittelschmerz, preclampsia, premature ejaculation, premature (preterm) labor or Raynaud's disease.

12. Use according to claim 11 wherein the disorder is dysmenorrhoea (primary or
20 secondary).

13. Use according to claim 12 wherein the disorder is primary dysmenorrhoea.

14. A pharmaceutical formulation including a compound according to any of claims 1 to
25 6 or a pharmaceutically acceptable derivative thereof, together with a pharmaceutically acceptable excipients, diluent or carrier;

15. A pharmaceutical product containing a V1a antagonist according to any of claims 1 to 6 in combination with a compound selected from (a) an oral contraceptive, (b) a PDE5
30 inhibitor, (c) an NO donor, (d) L-arginine, or (e) a COX inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of dysmenorrhoea.